Navigation Links
Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
Date:1/14/2009

SEATTLE, Jan. 14 /PRNewswire-FirstCall/ -- In meetings held in association with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and 2008 accomplishments. CTI is seeking to obtain two new drug approvals in 2009 in addition to potential label expansion for Zevalin(R). In November CTI established a 50/50 joint venture with Spectrum Pharmaceuticals, Inc. (Spectrum) for Zevalin.

"With a focus on cutting-edge oncology drug products, CTI aims to complete its transition from a research-based organization to a leading commercial oncology company," said James A. Bianco, M.D., CEO of Cell Therapeutics. "In 2008 we set the stage for becoming a multi-product commercial oncology operating company, with Zevalin currently under priority review by the FDA in the U.S. for label expansion, OPAXIO(TM) under review for market authorization application approval in Europe and, based on positive Phase III data for pixantrone, we expect to file a rolling NDA in 2009. Additionally, we continue to focus on improving our capital structure, streamlining our operations and significantly reducing our cash burn rate. With potential approval of pixantrone and OPAXIO in 2009, and potential sales revenue growth due to possible Zevalin label expansion, we are on target to accomplish our goal of reaching cashflow break-even in the fourth quarter of 2009," Bianco added.

Targeted 2009 Milestones:

ZEVALIN -- First- line consolidation indication approval for Zevalin with a target decision date by the FDA of April 2, 2009, based on a supplemental biologics license application (sBLA) submitted on October 2, 2008 for the use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. CTI and Spectrum have a joint venture for the sales, marketing and development of Z
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 Dr. Sparano is ... Women’s Health at the Albert Einstein College of Medicine ... the Montefiore Medical Center. He is also Associate ... and leads the Einstein Breast Cancer Working Group, a ... breast cancer research. He also serves as Vice Chair ...
(Date:5/17/2013)... provider of scientific, technical and medical information products and ... in Reproductive BioMedicine Online on ... abnormal chromosomal composition can be identified by the rate ... the risk of genetic abnormality without a biopsy. In ... retrospective study, using their predictive model to assess the ...
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine Group ... 50% enrollment of the total projected enrollment required ... safety and preliminary efficacy of the medical technology ... Knee Osteoarthritis (KOA). To date the trial has ... The Phase I open label clinical research ...
(Date:5/17/2013)... 17, 2013 Men’s skin is biologically different ... Posay ) and has been known to react more aggressively ... may be far from puberty, other acne causing factors like ... breakouts, and threatening skin with unsightly acne scars. Adult acne ... Men’s Health on how to reduce and prevent acne ...
Breaking Biology Technology:Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2
... Calif., Oct. 1 Vet-Stem, Inc. announced that Dr. ... a talk entitled "Stem Cell Therapy: Mechanisms of Action" ... of Veterinary Surgeons (ACVS) in Seattle, WA, October 21, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20060425/VETSTEMLOGO ) Dr. Harman ...
... a pilot-scale study wherein Kibow(R) Biotics were administered orally ... Argentina and Nigeria. The positive outcome from this study ... the peer-reviewed "Advances in Therapy" journal. This report, titled ... Kidney Function in Patients with Chronic Kidney Disease," can ...
... Oct. 1 Bioheart, Inc. - (OTC Bulletin Board: ... discovery, development and commercialization of autologous cell therapies for ... company received a preliminary commitment from Seaside National Bank ... used to refinance the Company,s loan with Bank of ...
Cached Biology Technology:Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting 2Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health 2Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health 3Bioheart, Inc. Announces Loan to be Assumed by Seaside 2Bioheart, Inc. Announces Loan to be Assumed by Seaside 3
(Date:5/16/2013)... living closer to a fast food restaurant had a ... further away from fast food, according to researchers at ... this association was particularly strong among those with a ... in the American Journal of Public Health ... fast food restaurant, and among lower-income African-Americans, the density, ...
(Date:5/16/2013)... The relationship between the heritable risk for ... clear. Schizophrenia is commonly associated with cognitive impairments ... that reduced IQ may be linked to the ... ability may precede the onset of schizophrenia symptoms. ... relatives of people diagnosed with schizophrenia. , In ...
(Date:5/16/2013)... Infections can trigger hematopoiesis at sites outside the bone ... skin.Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich now show that ... medullary" formation of blood cells. , Balanced hematopoiesis is ... fetal development, hematopoiesis takes place mainly in the liver ... the bone marrow, and this tissue normally serves as ...
Breaking Biology News(10 mins):Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Genetic risk for schizophrenia is connected to reduced IQ 2Herpes infections: Natural killer cells activate hematopoiesis 2
... Residential washing machines may not always use hot ... aureus (MRSA) and Acinetobacter, a Gram-negative bacteria, from hospital ... issue of Infection Control and Hospital Epidemiology , ... America. The study, conducted by researchers from ...
... SAN DIEGO (October 2, 2011) Researchers at the ... previously unknown mechanism that generates protective immune memory cells ... which include the mouth, the intestines, the lungs and other ... viruses and other infectious organisms. The findings were published ...
... the Institute for Genomic Biology (IGB) and the School ... NSF,s Integrative Graduate Education and Research Traineeship (IGERT) is ... 1998 and has, thus far, provided interdisciplinary research training ... of Illinois grant, Vertically Integrated Training With Genomics (VInTG), ...
Cached Biology News:Study: Residential washers may not kill hospital-acquired bacteria 2La Jolla Institute discovers novel mechanism for preventing infection via body's mucosal borders 2La Jolla Institute discovers novel mechanism for preventing infection via body's mucosal borders 3La Jolla Institute discovers novel mechanism for preventing infection via body's mucosal borders 4Institute for Genomic Biology, School of Integrative Biology receive major NSF training grant 2
Immunogen: Extract of pigmented melanoma metastases from lymph nodes. Storage: -20 C, Avoid Freeze/Thaw Cycles...
alpha N-catenin (C-19)...
... Immunogen: Synthetic peptide derived from the ... 36 protein This peptide sequence is ... another Zymed polyclonal Connexin 36 antibody Cat. ... Connexin 36. Reactivity: Mouse (positive control: ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
Biology Products: